|Articles|January 23, 2023
At-line Spent Media Analysis using the REBEL to Optimize a CHO mAb Fed-Batch Process
Author(s)908 Devices
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5